All In Biotech

Drug Trial Radar · NCT05225415

Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies

A Randomized, Double-blind, Placebo-controlled, Phase 2, 6-month Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies

Last checked: Nov 19, 2026Latest source record: Mar 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 130 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

130

Actual

Start

May 19, 2022

Primary completion

Nov 25, 2024

Study completion Nov 25, 2024

Sponsor

Lead sponsor
Cognition TherapeuticsIndustry
Sponsor type
Industry
Collaborators
National Institute on Aging (NIA)
First posted
Feb 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multi-center, randomized, double-blind, placebo-controlled, 6- month study in subjects with mild to moderate Dementia with Lewy Bodies.

Conditions

  • Dementia With Lewy Bodies

Interventions

  • CT1812Drug

    Orally administered CT1812

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Study Participants With at Least One Mild, Moderate, or Severe Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 210 Days

Locations

34 sites in 1 country. Site status is shown where the registry gives one.

  • Barrow Neurological Institute

    Phoenix, Arizona

  • Banner Sun Health Research Institute

    Sun City, Arizona

  • University of Arizona - Health Sciences Center

    Tucson, Arizona

  • Stanford University

    Palo Alto, California

  • Pacific Neuroscience Institute

    Santa Monica, California

  • University of Colorado

    Aurora, Colorado

  • CenExel Rocky Mountain Clinical Research, LLC

    Englewood, Colorado

  • New England Institute for Neurology and Headache (NEINH)

    Stamford, Connecticut

  • JEM Research Institute

    Atlantis, Florida

  • University of Miami Miller School of Medicine Comprehensive Center for Brain Health

    Boca Raton, Florida

  • Parkinson's Disease and Movement Disorders Center of Boca Raton

    Boca Raton, Florida

  • Charter Research

    Lady Lake, Florida

  • Renstar Medical Research

    Ocala, Florida

  • Charter Research

    Winter Park, Florida

  • Rush University Medical Center Section of Parkinson Disease and Movement Disorder

    Chicago, Illinois

  • IU Health Neuroscience Center, Goodman Hall

    Indianapolis, Indiana

  • Josephson Wallack Munshower Neurology, P.C

    Indianapolis, Indiana

  • The University of Kansas Alzheimer's Disease Research Center

    Fairway, Kansas

  • University of Kentucky

    Lexington, Kentucky

  • Headlands Research Eastern Massachusetts, LLC

    Plymouth, Massachusetts

  • Mayo Clinic

    Rochester, Minnesota

  • Columbia University

    New York, New York

  • UNC Department of Neurology

    Chapel Hill, North Carolina

  • Cleveland Clinic Main Campus

    Cleveland, Ohio

  • Ohio State University

    Columbus, Ohio

  • Summit Headlands, LLC

    Portland, Oregon

  • Oregon Health and Science University

    Portland, Oregon

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • University of Texas Southwestern

    Dallas, Texas

  • Clinical Trial Network

    Houston, Texas

  • University of Virginia Adult Neurology

    Charlottesville, Virginia

  • Virginia Commonwealth University

    Richmond, Virginia

  • Evergreen Health Research

    Kirkland, Washington

  • Universtiy of Washington Department of Neurology

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.